Intent to Sole Source - Olink Reagents

The National Institutes of Health, Clinical Center (NIH-CC) issued this special notice of intent to negotiate a sole source procurement with Olink Proteomics Inc. under solicitation number NOI-CC-OLAO-26-006363. The requirement is classified under NAICS 325414 Biological Product (except Diagnostic) Manufacturing and PSC 6550 IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS. There is no set-aside designated for this acquisition, identified by the code NONE and explanation NONE. The primary place of performance is Bethesda, Maryland.

The scope of this acquisition involves the procurement of reagents compatible with the Olink Q100 Instrument. Olink Proteomics Inc. is the manufacturer of the Q100 Instrument and is the only provider of the validated reagents required for its operation, as no other vendor produces compatible supplies. The NIH-CC intends to award this contract on an other than full and open competition basis under the statutory authority of 41 U.S.C. 253(c)(1), as implemented by FAR 6.302-1, which applies when only one responsible source can satisfy agency requirements.

The government published this notice on June 11, 2026, and will consider capability statements from responsible sources received by the deadline of 12:00 PM Eastern Standard Time on June 21, 2026. Submissions must include the reference number NOI-OLAO-CC-26-006363 in the subject line. Two attachments accompany this notice: a Justification and Approval PDF and a sole source justification Word document, both posted on June 11, 2026.